First patient dosed in Ph 1/2I study of MT-4561 in patients with advanced solid tumors
The Phase I/II study (NCT06943521), is a human, multicenter, open-label study, that evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of MT4561 in patients with advanced solid tumors. The clinical trial for MT-4561 will be conducted in 3 parts, across several sites, with the first part consisting of an intravenous infusion of MT-4561 once every week in 28-day cycle that evaluates the number of patients with adverse events and the incidence of dose limiting toxicities (DLT). The study details and doses of Part 2 (dose-optimization) and Part 3 (DrugDrug Interaction) will be available after review of applicable Part 1 results.
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the